TYR and melanoma: In 2004, Weide et al. launched a clinical trial in which protamine-stabilized mRNAs encoding Melan-A, Tyrosinase, gp100, Mage-A1, Mage-A3, and Survivin were used to treat melanoma patients (NCT00204607) [175].